DexCom, Inc. vs Stitch Fix Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Stitch Fix Inc trades at $2.74 (market cap $365.41M). The key difference: DexCom, Inc. is far larger — about 87.1× Stitch Fix Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Stitch Fix Inc for 31 Days on average.
| DXCM | SFIX | |
|---|---|---|
Market Cap | $31.81B | $365.41M |
Volume | 2,861,821 | 3,317,935 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $5.64 |
52-Week Low | $54.84 | $2.16 |
Typical Hold Time | 62 Days | 31 Days |
Enterprise Value | $31.26B | $261.21M |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Stitch Fix (SFIX) trades at $2.73, up 2.25% today, but remains under pressure with a bearish technical signal. Recent Q4 2026 earnings showed a narrower loss than expected, but revenue missed estimates and weak FY2027 guidance triggered an 18% stock drop. The company is navigating a challenging consumer environment while leveraging AI personalization to boost engagement. Fundamentals show improving net loss margins, but negative ROE and ROA persist.
The outlook is cautious. While cost controls are improving losses, declining active clients and soft revenue guidance pose headwinds. Analyst consensus is a $3.40 price target with a 'Hold' bias. Key risks include execution on growth initiatives, high client acquisition costs, and ongoing legal investigations. The stock offers speculative appeal if turnaround gains traction, but near-term volatility is likely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →